3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Neuroendocrine Tumors
6
Carcinoid Tumor
5
Neoplasms
4
Carcinoma
3
Vipoma
2
Neoplasm Metastasis
2
Intestinal Obstruction
2
Carcinoma, Islet Cell
2
Somatostatinoma
1
Recurrence
1
Prostatic Neoplasms
1
Primary Inoperable Thymoma
1
Pleural Effusion
1
Peritoneal Neoplasms
1
Malignant Carcinoid Syndrome
1
Lymphangiomyoma
1
Lymphangioleiomyomatosis
1
Insulinoma
1
Glucagonoma
1
Gastro-enteropancreatic neuroendocrine tumor
1
Gastrinoma
1
Diarrhea
1
Chylous Ascites
1
Chylothorax
1
Carcinoma, Neuroendocrine
1
Breast Neoplasms
1
Ascites
1
Adenoma, Islet Cell
1
Interventions
Sunitinib
16
Imatinib Mesylate
13
nilotinib
8
ripretinib
4
regorafenib
4
avapritinib
3
4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one
3
pexidartinib
2
pembrolizumab
2
Bevacizumab
2
trametinib
1
tinostamustine
1
spartalizumab
1
romidepsin
1
ponatinib
1
pazopanib
1
palbociclib
1
olaratumab
1
guadecitabine
1
ferric carboxymaltose
1
epacadostat
1
dabrafenib
1
cediranib
1
Surveys and Questionnaires
1
Surgical Procedures, Operative
1
Sorafenib
1
STA 9090
1
Observation
1
Iron-Dextran Complex
1
Indocyanine Green
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Has results
×
Gastrointestinal Stromal Tumors
×
Octreotide
×
Clear all
No trials found.